Regeneron Pharmaceuticals
$735.20Change from previous close: +0.05%Absolute change: +$0.39
At a glance
- Revenue growth
- +0.99%
- 2025 vs 2024
- Net income growth
- +2.09%
- 2025 vs 2024
- Net margin
- 31.4%
- 2024: 31.1%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 813 | 1,079 | 1,171 | 1,619 | 1,144 | 1,045 | 1,263 | 1,291 | 354 | 1,513 | 1,090 | 1,114 |
| Depreciation and amortization | 124 | 123 | 145 | 137 | 135 | 127 | 126 | 122 | 121 | 114 | 113 | 105 |
| Capital expenditure | -240 | -231 | -249 | -201 | -219 | -229 | -200 | -242 | -181 | -134 | -251 | -176 |
| Investing cash flow | -92.7 | -429 | 220 | -403 | -1,094 | 648 | 351 | -574 | -557 | -1,687 | -66.2 | -496 |
| Financing cash flow | -1,225 | -802 | -780 | -718 | -1,128 | -1,089 | -1,136 | -634 | -478 | 47.1 | -446 | -407 |
| Dividends paid | -96.8 | -97.8 | -92.7 | -91.2 | -92.6 | -93.8 | — | — | — | — | — | — |
| Share repurchases | -1,177 | -868 | -1,191 | -667 | -1,067 | -1,046 | -1,226 | -855 | -916 | -635 | -747 | -676 |
| Effect of exchange rates | -0.3 | -0.9 | -0.3 | -0.4 | 0.4 | 0.6 | -0.7 | 0.8 | -0.3 | -0.5 | 0.2 | -0.2 |
| Net change in cash | -505 | -153 | 611 | 498 | -1,077 | 604 | 477 | 83.6 | -682 | -128 | 578 | 211 |
| Free cash flow | 573 | 848 | 922 | 1,417 | 925 | 816 | 1,063 | 1,049 | 174 | 1,379 | 838 | 938 |
| Levered free cash flow | 383 | 577 | 684 | 1,422 | 591 | 562 | 936 | 761 | -177 | 1,115 | 548 | 623 |